Author

D. Batlle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pathology· 2 Immunology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Organism:human· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Wysocki· 4 shared A. Tomatsidou· 2 shared G. Randall· 2 shared H. Gula· 2 shared I. Gelarden· 2 shared J. Henkin· 2 shared L. Hassler· 2 shared M. Ye· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPathology

J. Wysocki

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection

L. Hassler, J. Wysocki, J. T. Ahrendsen, M. Ye, I. Gelarden, V. Nicolaescu, A. Tomatsidou, H. Gula, C. Cianfarini, N. Khurram, Y. Kanwar, B. D. Singer, G. Randall, D. M. Missiakas, J. Henkin, D. Batlle

This study compares intranasal and systemic administration of bioengineered soluble ACE2 in mice, finding intranasal delivery provides better survival and brain protection against SARS-CoV-2.

bioRxiv · Dec 5, 2022 · PreprintPathology

A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection

L. Hassler, J. Wysocki, I. Gelarden, A. Tomatsidou, H. Gula, V. Nicoleascu, G. Randall, J. Henkin, A. Yeldandi, D. Batlle

This paper describes a soluble ACE2 protein that prevents lethal SARS-CoV-2 infection in mice by blocking viral entry and reducing viral titers.

bioRxiv · Mar 12, 2021 · PreprintPathology

Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Virus Infection as an Innate Antiviral Mechanism

L. El-Shennawy, A. D. Hoffmann, N. K. Dashzeveg, P. J. Mehl, Z. Yu, V. L. Tokars, V. Nicolaescu, C. Ostiguin, Y. Jia, L. Li, K. Furlong, C. Mao, J. Wysocki, D. Batlle, T. J. Hope, , H. Liu

The paper shows that ACE2-expressing exosomes in plasma block SARS-CoV-2 infection by competing with cellular ACE2, offering a new innate antiviral mechanism.

bioRxiv · Dec 3, 2020Immunology

Kidney and Lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19

J. Wysocki, E. Lores, M. Ye, M. J. Soler, D. Batlle

This study examines how ACE inhibitors and Ang II receptor blockers affect ACE2 expression in kidney and lung tissues, finding no significant increase that would suggest a risk for SARS-CoV-2 infection.

bioRxiv · May 20, 2020Physiology